K M Klassen1,2, M G Kimlin3, C K Fairley4, S Emery5, P H Anderson6, P R Ebeling7,8. 1. Department of Medicine, University of Melbourne, Victoria, 3021, Australia. karenklassen@gmail.com. 2. Melbourne Sexual Health Centre, Alfred Health, 580 Swanston Street, Carlton, Melbourne, Victoria, Australia. karenklassen@gmail.com. 3. AusSun Research Lab, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia. 4. Central Clinical School, Alfred Centre, Monash University, Melbourne, 3004, Australia. 5. The Kirby Institute, University of New South Wales, Sydney, Australia. 6. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia. 7. Department of Medicine, University of Melbourne, Victoria, 3021, Australia. 8. Department of Medicine, School of Clinical Sciences, Monash University, Monash Health, Clayton, 3168, Victoria, Australia.
Abstract
RATIONALE: To see if vitamin D and antiretroviral therapy are associated with bone mineral density (BMD) in people with HIV. RESULT: Lower hip BMD was associated with tenofovir (an antiretroviral medicine) in those with 25(OH)D ≥50 nmol/L. SIGNIFICANCE: The relationship between antiretroviral therapy and hip BMD differs depending on vitamin D status. INTRODUCTION:People with HIV have an increased risk of low BMD and fractures. Antiretroviral therapy contributes to this increased risk. The aim of this study was to evaluate associations between vitamin D metabolites and antiretroviral therapy on BMD. METHODS: The simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine trial (STEAL) was an open-label, prospective randomised non-inferiority study that compared simplification of current nucleoside reverse transcriptase inhibitors (NRTIs) to fixed-dose combination tenofovir-emtricitabine (TDF-FTC) or abacavir-lamivudine. Serum 25(OH)D and 1,25(OH)2D were measured in 160 individuals (90 receiving TDF-FTC, 70 receiving other NRTIs) at baseline from this study. Multivariable linear regression models were constructed to evaluate the covariates of 1,25(OH)2D and BMD. RESULTS: Protease inhibitor use (p = 0.02) and higher body mass index (BMI) (p = 0.002) were associated with lower 1,25(OH)2D levels in those with 25(OH)D <50 nmol/L. However, TDF-FTC use (p = 0.01) was associated with higher 1,25(OH)2D levels, but only in those with 25(OH)D ≥50 nmol/L. White ethnicity (p = 0.02) and lower BMI (p < 0.001) in those with 25(OH)D <50 nmol/L and with TDF-FTC use (p = 0.008) in those with 25(OH)D ≥50 nmol/L were associated with lower hip BMD. TDF-FTC use, higher serum calcium and serum βCTX, winter, and lower bone-specific alkaline phosphatase (BALP) and BMI were associated with lower lumbar spine BMD. CONCLUSION:TDF-FTC use (versus non-TDF-FTC use) was associated with lower hip BMD, and this difference was more pronounced in those with 25(OH)D ≥50 nmol/L. Serum 25(OH)D <50 nmol/L was associated with lower hip BMD in all participants. Therefore, the associations between antiretroviral therapy and hip BMD differ depending on vitamin D status.
RCT Entities:
RATIONALE: To see if vitamin D and antiretroviral therapy are associated with bone mineral density (BMD) in people with HIV. RESULT: Lower hip BMD was associated with tenofovir (an antiretroviral medicine) in those with 25(OH)D ≥50 nmol/L. SIGNIFICANCE: The relationship between antiretroviral therapy and hip BMD differs depending on vitamin D status. INTRODUCTION:People with HIV have an increased risk of low BMD and fractures. Antiretroviral therapy contributes to this increased risk. The aim of this study was to evaluate associations between vitamin D metabolites and antiretroviral therapy on BMD. METHODS: The simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine trial (STEAL) was an open-label, prospective randomised non-inferiority study that compared simplification of current nucleoside reverse transcriptase inhibitors (NRTIs) to fixed-dose combination tenofovir-emtricitabine (TDF-FTC) or abacavir-lamivudine. Serum 25(OH)D and 1,25(OH)2D were measured in 160 individuals (90 receiving TDF-FTC, 70 receiving other NRTIs) at baseline from this study. Multivariable linear regression models were constructed to evaluate the covariates of 1,25(OH)2D and BMD. RESULTS: Protease inhibitor use (p = 0.02) and higher body mass index (BMI) (p = 0.002) were associated with lower 1,25(OH)2D levels in those with 25(OH)D <50 nmol/L. However, TDF-FTC use (p = 0.01) was associated with higher 1,25(OH)2D levels, but only in those with 25(OH)D ≥50 nmol/L. White ethnicity (p = 0.02) and lower BMI (p < 0.001) in those with 25(OH)D <50 nmol/L and with TDF-FTC use (p = 0.008) in those with 25(OH)D ≥50 nmol/L were associated with lower hip BMD. TDF-FTC use, higher serum calcium and serum βCTX, winter, and lower bone-specific alkaline phosphatase (BALP) and BMI were associated with lower lumbar spine BMD. CONCLUSION:TDF-FTC use (versus non-TDF-FTC use) was associated with lower hip BMD, and this difference was more pronounced in those with 25(OH)D ≥50 nmol/L. Serum 25(OH)D <50 nmol/L was associated with lower hip BMD in all participants. Therefore, the associations between antiretroviral therapy and hip BMD differ depending on vitamin D status.
Entities:
Keywords:
Antiretroviral therapy; Bone; HIV; Vitamin D
Authors: Mar Masiá; Sergio Padilla; Catalina Robledano; Natividad López; José Manuel Ramos; Felix Gutiérrez Journal: AIDS Res Hum Retroviruses Date: 2011-07-19 Impact factor: 2.205
Authors: Caryl A Nowson; John J McGrath; Peter R Ebeling; Anjali Haikerwal; Robin M Daly; Kerrie M Sanders; Markus J Seibel; Rebecca S Mason Journal: Med J Aust Date: 2012-06-18 Impact factor: 7.738
Authors: E A Greco; R Fornari; F Rossi; V Santiemma; G Prossomariti; C Annoscia; A Aversa; M Brama; M Marini; L M Donini; G Spera; A Lenzi; C Lubrano; S Migliaccio Journal: Int J Clin Pract Date: 2010-05 Impact factor: 2.503
Authors: Allison Martin; Mark Bloch; Janaki Amin; David Baker; David A Cooper; Sean Emery; Andrew Carr Journal: Clin Infect Dis Date: 2009-11-15 Impact factor: 9.079
Authors: Alexandra Calmy; Christoph A Fux; Richard Norris; Nathalie Vallier; Cécile Delhumeau; Katherine Samaras; Karl Hesse; Bernard Hirschel; David A Cooper; Andrew Carr Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226
Authors: Heike A Bischoff-Ferrari; Douglas P Kiel; Bess Dawson-Hughes; John E Orav; Ruifeng Li; Donna Spiegelman; Thomas Dietrich; Walter C Willett Journal: J Bone Miner Res Date: 2009-05 Impact factor: 6.741
Authors: Karen Klassen; Adrian R Martineau; Robert J Wilkinson; Graham Cooke; Alan P Courtney; Mary Hickson Journal: PLoS One Date: 2012-09-12 Impact factor: 3.240
Authors: Lediya T Cheru; Charles F Saylor; Kathleen V Fitch; Sara E Looby; Michael Lu; Udo Hoffmann; Takara L Stanley; Janet Lo Journal: Antivir Ther Date: 2019